期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 54, 期 2, 页码 610-613出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00886-09
关键词
-
资金
- Johnson and Johnson
- College des Universitaires de Maladies Infectieuses et Tropicales (CMIT)
- Association pour la Formation et la Recherche en Reanimation et en Infectiologie (AFRRI)
- Microbial Pathogenesis and Host Defense Postdoctoral Fellowship, University of California, San Francisco [5T32AI060537-02]
Beta lactam agents are the most active drugs for the treatment of streptococci and methicillin-susceptible Staphylococcus aureus endocarditis. However, methicillin-resistant S. aureus (MRSA) is resistant to all beta lactam agents licensed to date, and alternative treatments are limited. Ceftobiprole is a novel broad-spectrum cephalosporin that binds with high affinity to PBP 2a, the penicillin binding protein that mediates the methicillin resistance of staphylococci and is active against MRSA. Ceftobiprole was compared to vancomycin, daptomycin, and linezolid in a rabbit model of MRSA aortic valve endocarditis caused by the homogeneously methicillin-resistant laboratory strain COL. Residual organisms in vegetations were significantly fewer in ceftobiprole-treated rabbits than in any other treatment group (P < 0.05 for each comparison). In addition, the numbers of organisms in spleens and in kidneys were significantly lower in ceftobiprole-treated rabbits than in linezolid- and vancomycin-treated animals (P < 0.05 for each comparison). Anti-MRSA beta lactam agents such as ceftobiprole may represent a significant therapeutic advance over currently available agents for the treatment of MRSA endocarditis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据